Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Receivables (2019 - 2025)

Eton Pharmaceuticals' Receivables history spans 7 years, with the latest figure at $13.1 million for Q3 2025.

  • For Q3 2025, Receivables rose 133.98% year-over-year to $13.1 million; the TTM value through Sep 2025 reached $13.1 million, up 133.98%, while the annual FY2024 figure was $5.4 million, 57.17% up from the prior year.
  • Receivables for Q3 2025 was $13.1 million at Eton Pharmaceuticals, down from $14.5 million in the prior quarter.
  • Across five years, Receivables topped out at $16.4 million in Q1 2025 and bottomed at $300000.0 in Q1 2021.
  • The 5-year median for Receivables is $3.4 million (2023), against an average of $4.6 million.
  • The largest annual shift saw Receivables soared 10316.67% in 2021 before it crashed 62.96% in 2022.
  • A 5-year view of Receivables shows it stood at $5.0 million in 2021, then tumbled by 62.96% to $1.9 million in 2022, then soared by 84.18% to $3.4 million in 2023, then surged by 57.17% to $5.4 million in 2024, then skyrocketed by 144.02% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Receivables are $13.1 million (Q3 2025), $14.5 million (Q2 2025), and $16.4 million (Q1 2025).